Japan: Data from the real-world POPCORN registry has revealed thatperipheral artery disease (PAD)patients onhemodialysisexperience worse vessel patency afterdrug-coated balloon (DCB)interventions compared to non-dialysis patients. However, 3-year limb salvage rates remain high, exceeding 90%. The findings, published inJACC: Cardiovascular Interventionsby Yasutaka Yamauchi of the Cardiovascular Center, Takatsu General Hospital, Kawasaki, and colleagues, suggest important insights into long-term outcomes of DCB therapy in a high-risk population that has traditionally been underrepresented in large-scale vascular studies. The study analyzed data from a prospective, multicenter registry that included patients treated with DCBs—either Lutonix or IN.PACT Admiral—for femoropopliteal artery disease between March 2018 and December 2019. Of the 3,165 lesions treated, 991 were in patients undergoing hemodialysis. The primary outcome of interest was freedom from restenosis over three years. The study led to the following findings: The authors wrote, "DCB endovascular therapy represents a viable and effective treatment option for managing femoropopliteal lesions in patients undergoing hemodialysis. While the durability of vessel patency may be somewhat reduced in this high-risk group, the consistently high rates of limb preservation highlight its clinical value." They emphasize the importance of adopting a tailored approach to endovascular care—one that takes into account specific anatomical and procedural factors—to optimize long-term outcomes in patients on dialysis. Yamauchi, Y, Takahara, M, Soga, Y. et al. Vessel Patency After Femoropopliteal Drug-Coated Balloon Therapy in Patients on Hemodialysis. J Am Coll Cardiol Intv. 2025 Jul, 18 (13) 1660–1670. https://doi.org/10.1016/j.jcin.2025.05.001